Clinical Report: Merck TROP2 ADC Meets Phase 3 Endpoints in Endometrial Cancer
Overview
Merck's investigational TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), has met its dual primary endpoints of overall survival and progression-free survival in a phase 3 trial for advanced or recurrent endometrial cancer.
Background
Endometrial cancer treatment has evolved significantly, particularly for patients who have progressed after platinum-based chemotherapy and anti-PD-1/L1 therapy. The introduction of novel therapies, such as antibody-drug conjugates, represents an advancement in managing this patient population.
Data Highlights
Endpoint
Outcome
Overall Survival
Met
Progression-Free Survival
Met
Key Findings
Sac-TMT met dual primary endpoints of overall survival and progression-free survival.
The trial involved patients with advanced or recurrent endometrial cancer after prior platinum and anti-PD-1/L1 therapy.
This is the first positive phase 3 readout from Merck’s TroFuse program.
The study compared sac-TMT against physician’s choice chemotherapy.
Merck has 17 ongoing global phase 3 trials across multiple tumor types.
Clinical Implications
The findings from the TroFuse-005 trial may provide a new treatment option for patients with advanced or recurrent endometrial cancer who have limited alternatives. Clinicians should consider the implications of these results in the context of evolving treatment guidelines.
Conclusion
The successful outcomes of the TroFuse-005 trial highlight the potential of sac-TMT as a viable therapeutic option in advanced endometrial cancer. Continued research and trials will be essential to further validate these findings.
Lung cancer resulted in 1.8 million deaths globally in 2022 and remains the leading cause of cancer-related mortality worldwide. Low-dose CT screening has been shown to reduce lung cancer mortality, a...
